Delivra Health Brands Enters Into Licence Agreement With Canopy Growth to Manufacture and Distribute Its Leading Infused Topical Brand LivRelief(TM)
Delivra Health Brands Enters Into Licence Agreement With Canopy Growth to Manufacture and Distribute Its Leading Infused Topical Brand LivRelief(TM)
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) (formerly, Harvest One Cannabis Inc.) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, announced today that its wholly-owed subsidiary, Delivra Inc., has granted a subsidiary of Canopy Growth Corporation ("Canopy"), a leading global cannabis company, an exclusive strategic licence agreement dated May, 23, 2023 ("Licence Agreement") to manufacture, distribute and sell infused LivRelief TM branded topicals in Canada.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年5月24日)-Delivra Health Brands Inc.(TSXV：DHB)(OTCQB：DHBUF)(前身為嘉實一號大麻公司)(“Delivra Health“或”公司)今天宣佈，其全資子公司Delivra Inc.已將Canopy Growth Corporation(天篷全球領先的大麻公司)簽署了一份日期為2023年5月23日的獨家戰略許可協定(許可協定“)製造、分銷和銷售注入的LivRelipmentTM加拿大的品牌專題。
"We are very pleased to announce our second agreement with Canopy, this time to secure more efficient and cost effective supply and distribution for our LivReliefTM infused branded topicals, such as the transdermal cream that ranked as the top selling transdermal cream in Canada as of January 2023,"1 said Gord Davey, President and Chief Executive Officer of Delivra Health. "We expect our collaboration with Canopy will realize benefits well beyond the availability of our product on Canopy's Spectrum Therapeutics' online medical store. Through the agreement, Canopy will be responsible for manufacturing, distributing and selling the of LivReliefTM products in Canada, and we strongly believe that as an industry leader, Canopy will be able to grow the LivRelief TM brand to its full potential."
我們非常高興地宣佈我們與Canopy達成了第二項協定，這一次是為了確保我們LivRelipment更高效、更具成本效益的供應和分銷TM注入品牌局部用藥，例如截至2023年1月在加拿大最暢銷的透皮乳膏，1德利夫拉健康公司首席執行官總裁和Gord Davey說。我們預計我們與Canopy的合作將實現遠遠超過我們產品在Canopy的Spectrum Treateutics在線醫療商店上提供的好處。通過協定，Canopy將負責製造、分銷和銷售LivRelipedTM產品在加拿大，我們堅信，作為行業領先者，Canopy將能夠成長為LivRelipedTM充分發揮品牌的潛力。
LivReliefTM cannabis infused products are available nationally through Medical Cannabis by Shoppers as well as in cannabis stores throughout Ontario, British Columbia, Alberta, Saskatchewan, Manitoba, and New Brunswick.
活體浮雕TM在全國範圍內，購物者可以通過醫用大麻購買注入大麻的產品，也可以在安大略省、不列顛哥倫比亞省、艾伯塔省、薩斯喀徹溫省、馬尼託巴省和新不倫瑞克省的大麻商店購買。
LivReliefTM infused topicals are currently available in three unique SKUs - a CBD-only formulation containing 250mgs of CBD, a 1:1 format formulation containing 125mgs of THC and 125mgs of CBD, and an extra strength CBD topical cream containing 750mgs of CBD.
活體浮雕TM目前有三種獨特的SKU可供選擇--一種僅含250毫克CBD的CBD配方，一種含有125毫克THC和125毫克CBD的1：1配方，以及一種含有750毫克CBD的超強CBD外用乳膏。
Note:
注：
1. Source: Trellis January 2023 data
1.數據來源：Trellis 2023年1月數據
About Delivra Health Brands Inc.
關於Delivra Health Brands Inc.
Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water and LivRelief, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are Dream WaterTM and LivReliefTM. For more information, please visit .
幫助人們通過替代健康解決方案控制自己的健康是Delivra Health團隊的動力所在！Delivra Health產品組合以夢幻水和LivRelipment等創新品牌為特色，這些品牌可以緩解慢性疼痛、焦慮和失眠等常見的日常問題。Delivra保健產品讓數百萬客戶重新獲得了他們的機動性、能量和生活品質。公司的兩個子公司的網站是夢之水TM和LivRelipmentTM。欲瞭解更多資訊，請訪問。
Cautionary Note Regarding Forward-Looking Statements
有關前瞻性陳述的注意事項
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to future supply and distribution of LivReliefTM infused branded topicals, projected rankings of LivReliefTM transdermal creams, projected benefits to the Company from the Licence Agreement, cost efficiencies to be created by the Licence Agreement, the Company's growth objectives, increasing revenues and profitability, growth in new markets, and new distribution partners.
本新聞稿包含適用於加拿大證券法的“前瞻性資訊”和“前瞻性陳述”(統稱為“前瞻性陳述”)。除有關歷史事實的陳述外，所有陳述均為前瞻性陳述，均基於截至本新聞稿發佈之日的預期、估計和預測。任何涉及關於預測、期望、信念、計劃、預測、目標、假設、未來事件或業績的討論的陳述(經常但不總是使用諸如“預期”或“不預期”、“預計”、“預期”或“不預期”、“計劃”、“預算”、“預定”、“預測”、“估計”、“相信”或“打算”或這些詞語和短語的變體，或陳述某些行動、事件或結果“可能”或“可能”、“將”，“可能”或“將”被視為發生或實現)不是歷史事實的陳述，可能是前瞻性陳述。在本新聞稿中，前瞻性陳述包括，除其他事項外，有關LivRelipment未來供應和分銷的陳述TM注入品牌話題，生活救濟預測排名TM透皮霜、許可協定為公司帶來的預期利益、許可協定將創造的成本效益、公司的增長目標、增加收入和盈利能力、新市場的增長以及新的分銷合作夥伴。
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
這些前瞻性陳述是基於作出這些陳述時公司管理層的合理假設和估計。由於前瞻性陳述涉及已知和未知的風險、不確定因素和其他因素，可能導致公司的實際結果、業績或成就與此類前瞻性陳述明示或暗示的未來結果、業績或成就大不相同，因此未來的實際結果可能大不相同。這些因素包括：總體宏觀經濟狀況的波動；證券市場的波動；對公司經營的大麻市場規模的預期；消費者習慣的變化；公司成功實現其業務目標的能力；擴張計劃；政治和社會的不確定性；無法獲得足夠的保險以承保風險和危害；員工關係以及可能對公司經營的市場的大麻和大麻相關產品的種植、生產、分銷和銷售施加限制的法律法規的存在。儘管本新聞稿中包含的前瞻性陳述是基於公司管理層認為或當時被認為是合理假設的，但公司不能向股東保證實際結果將與這些前瞻性陳述一致，因為可能存在其他因素導致結果與預期、估計或預期的結果不一致。讀者不應過分依賴本新聞稿中包含的前瞻性陳述和資訊。除非法律要求，否則公司不承擔更新關於信念、意見、預測或其他因素的前瞻性陳述的義務。
Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated March 2, 2021, and under the heading "Risks and Uncertainties" in the Company's management's discussion and analysis dated May 23, 2023, for the three and nine months ended March 31, 2023, filed under the Company's profile on SEDAR at .
有關這一風險和與公司業務有關的其他風險和不確定因素的更多資訊，載於公司日期為2021年3月2日的公司年度資訊表中的“風險因素”標題，以及公司管理層於2023年5月23日提交的截至2023年3月31日的三個月和九個月的管理討論和分析中的“風險和不確定因素”標題下。
Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.
多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所-V的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934
投資者關係：
傑克·塔斯
首席財務官
郵箱：ir@delivraHealth.com
電話：1-877-915-7934
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。